Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364651 | 0.85 | MAOB (0.40) | MAOBTRPA1 | |
| SCHEMBL1338455 | 0.78 | HRH3 (0.35) | — | |
| SCHEMBL9908257 | 0.78 | TRPA1 (0.48) | MAOBTRPA1 | |
| SCHEMBL418183 | 0.78 | TRPA1 (0.48) | MAOBTRPA1 | |
| SCHEMBL3392101 | 0.77 | HRH3 (0.43) | MAOB | |
| SCHEMBL18160981 | 0.76 | CYP2A6 (0.46) | — | |
| SCHEMBL2929000 | 0.76 | CYP2A6 (0.46) | — | |
| SCHEMBL28253542 | 0.76 | TRPA1 (0.47) | MAOBTRPA1 | |
| Hydrochloric Acid SCHEMBL21352581 | 0.74 | HRH3 (0.41) | MAOB | |
| SCHEMBL4628332 | 0.72 | TRPA1 (0.46) | MAOBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221182-B2 | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-03-05 | — | — | US | disclosed |
| US-10221182-B2 | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-03-05 | — | — | US | disclosed |
| US-20180030055-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-02-01 | — | — | US | disclosed |
| US-20180030055-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-02-01 | — | — | US | disclosed |
| WO-2016126869-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126869-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-08-11 | — | — | WO | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | MAOB 412/4885TRPA1 3697/4885 |
| US-20180030055-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | MAOB 801/4885TRPA1 608/4885 |
| US-10221182-B2 | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | MAOB 801/4885TRPA1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.